HIV/AIDS: What is the impact on prevention of blindness programmes?

Community Eye Health

Volumn 16, Issue 47, 2003, Pages 33-34

  Lewallen, Susan ^a  

^a Ophthalmology   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; FLUOROURACIL; MITOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLINDNESS; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; EYE CANCER; HEALTH CARE ACCESS; HEALTH PROGRAM; HERPES ZOSTER OPHTHALMICUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDUSTRIALIZATION; KAPOSI SARCOMA; PREVALENCE; PREVENTIVE MEDICINE; RETINITIS; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING;

EID: 2542433990     PISSN: 09536833     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (3)

1. Morgan D, Mahe C, Malamba S, Okongo M, Mayanja B, Whitworth J. Herpes zoster and HIV-1 infection in a rural Ugandan cohort. J AIDS 2001; 15(2): 223-229.
2. Mahomed A, Chetty R. Human immunodeficiency virus infection, Bcl-2, p53 protein, and Ki-67 analysis in ocular surface squamous neoplasia. Arch Ophthalmol 2002; 120(5): 554-558.
3. Kestelyn P G, Cunningham E T. HIV/AIDS and blindness. Bull World Health Organ 2001; 79: 208-213.